Beskrywing

According to NIH, autoimmune disorders are conditions in which the body’s immune system mistakenly attacks and destroys healthy tissues of the body by perceiving them as foreign bodies. The majority of autoimmune disorders cause inflammation of affected parts of the body. The most commonly occurring autoimmune disorder include psoriasis, systemic lupus erythematosus, and rheumatoid arthritis, among others. The global autoimmune disorder drugs market in terms of revenue is set to grow by US$ 40 miljard tydens 2021-2027, groei teen 'n saamgestelde jaarlikse groeikoers (CAGR) van 9.8% gedurende die voorspellingsperiode, volgens die data- en ontledingsmaatskappy StrategyHelix. Growth in the geriatric population, increasing prevalence of autoimmune disorders, the rise in technological advancements for the diagnosis of autoimmune diseases are expected to boost the market growth in the coming years.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2017-2020 en voorspel tot 2027 covering key market aspects like sales value for autoimmune disorder drugs. The global autoimmune disorder drugs market is segmented on the basis of type, indication, region. Volgens tipe, it is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), and Immunosuppressant drugs. The NSAIDs segment held the largest market share in 2020. By indication, the autoimmune disorder drugs market is divided into rheumatoid arthritis, systemic lupus erythematosus, psoriasis/psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, tipe 1 diabetes, en ander. The rheumatoid arthritis segment accounted for the largest market share in 2020. Based on region, the autoimmune disorder drugs market is divided into North America, Asiatiese Stille-Oseaan, Europa, and Rest of the World (ROW).

The report has profiled some of the key players of the market such as AbbVie Inc., Amgen Inc., AstraZeneca plc, Bayer AG, Bristol Myers Squibb (BMS), Johnson & Johnson, Mylan N.V., Novartis AG, Pfizer Inc., Roche Holding AG, Vertex Pharmaceuticals Inc..

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the autoimmune disorder drugs market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Tik: nonsteroidal anti-inflammatory drugs (NSAIDs), and Immunosuppressant drugs
Indication: rheumatoid arthritis, systemic lupus erythematosus, psoriasis/psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, tipe 1 diabetes, en ander
Streek: Noord-Amerika, Asiatiese Stille-Oseaan, Europa, and Rest of the World (ROW)
Jare oorweeg: hierdie verslag dek die tydperk 2017 aan 2027

Sleutelvoordele vir belanghebbendes

Get a comprehensive picture of the global autoimmune disorder drugs market
Bepaal groeisektore en -neigings vir belegging
Understand what the future of the global autoimmune disorder drugs market looks like
Identifiseer die mededingende landskap en geleentheidsvenster

INHOUDSOPGAWE

1. Markdefinisie
2. Navorsingsmetodologie
3. Markdata & Outlook
3.1 Markwaarde
3.2 Markwaarde Voorspelling
4. Autoimmune Disorder Drugs Market by Type
4.1 Nonsteroidal Anti-Inflammatory Drugs (Nsaids)
4.2 Immunosuppressant Drugs
5. Autoimmune Disorder Drugs Market by Indication
5.1 Rheumatoid Arthritis
5.2 Systemic Lupus Erythematosus
5.3 Psoriasis/Psoriatic Arthritis
5.4 Multiple Sclerosis
5.5 Inflammatory Bowel Disease
5.6 Tik 1 Diabetes
5.7 Ander
6. Autoimmune Disorder Drugs Market by Region
6.1 Noord-Amerika
6.2 Asiatiese Stille-Oseaan
6.3 Europa
6.4 Rest Of The World (Row)
7. Maatskappy profiele
7.1 AbbVie Inc.
7.2 Amgen Inc.
7.3 AstraZeneca plc
7.4 Bayer AG
7.5 Bristol Myers Squibb (BMS)
7.6 Johnson & Johnson
7.7 Mylan N.V.
7.8 Novartis AG
7.9 Pfizer Inc.
7.10 Roche Holding AG
7.11 Vertex Pharmaceuticals, Inc.
8. Bylaag
8.1 Oor StrategyHelix
8.2 Vrywaring